Articles tagged with Sars Cov 2
A study published in Science Advances found that cannabidiol (CBD) inhibited SARS-CoV-2 infection in human cells and mice, suggesting its potential as a preventative or early treatment for COVID-19. CBD's effects were confined to high purity doses and specific situations.
Scientists at University of Texas M. D. Anderson Cancer Center and Northwestern Medicine identified naturally occurring vesicles containing ACE2 protein in patients' blood that can prevent or treat SARS-CoV-2 infection. These evACE2 act as decoys to lure the virus away from cells, preventing infection.
The study reveals that Omicron's spike protein mutations increase its binding affinity to human cells and evade antibodies, contributing to its increased transmissibility. The researchers aim to develop more effective treatments against Omicron and related variants using this knowledge.
Researchers report COVID-19 can cause a range of neurological symptoms, including loss of taste and smell, headaches, and brain inflammation. A new study suggests Long Covid may share common risk factors with myalgic encephalomyelitis/chronic fatigue syndrome.
Scientists have identified natural nano-bubbles containing the ACE2 protein in COVID-19 patients' blood, which can block infection from broad strains of SARS-CoV-2 virus. These nano bubbles serve as a decoy to lure the virus away from cells, preventing infection.
A newly developed decoy protein has been found to be highly effective in preventing death and lung damage in humanized animal models of severe COVID-19 disease. The treatment works by competing for the spike protein of SARS-CoV-2, thereby neutralizing the virus before it can bind and enter cells.
A recent study by UCLA Health researchers found no evidence of SARS-CoV-2 transmission through breast milk feeding. The study analyzed breastmilk samples from 110 lactating women and discovered that even when mothers had COVID-19, the virus was not present in their infants.
Researchers at Georgia State University found that newer variants of SARS-CoV-2 can infect the respiratory tract of wild mice, replicating in their lungs. This evolution highlights the virus's ability to mutate and spread in rodents living near humans.
Researchers created a novel molecular diagnostic platform that can detect COVID-19 genes after only 8 cycles of amplification, significantly reducing the time required for diagnosis. The new SERS-PCR platform uses gold nanoparticles to produce high-sensitivity signals, providing an important tool in the fight against the pandemic.
Researchers at Karolinska Institutet found that memory T cells formed after previous infection or mRNA vaccination can still recognize the omicron variant, suggesting protection against severe disease. The study also suggests booster immunization may provide benefits beyond neutralizing antibodies.
A Brazilian study found a correlation between dealing with COVID-19 and environmental disasters, highlighting the need for improved infrastructure and community resilience. The study also identified a lack of continuity in funding for disaster relief and pandemic response.
A recent study published in Pediatric Research found no SARS-CoV-2 genetic material in breastmilk from mothers infected with COVID-19, ruling out transmission to infants. The authors analyzed 110 lactating women and did not find any clinical evidence of infection in breastfeeding infants.
Vaccination prioritization aims to reduce mortality and epidemic progression by targeting older individuals, minimizing selection pressure on virus variants. By considering evolutionary dynamics alongside epidemic dynamics, researchers can develop effective vaccine strategies to combat emerging variants.
Researchers found elevated protein levels and unexpected antibodies in cerebrospinal fluid of patients with post-COVID cognitive symptoms, suggesting inflammation and a systemic response. The study suggests an activated immune system may be the cause of brain fog, a common after-effect of COVID-19.
Researchers have developed a label-free detection technique that digitally counts intact SARS-CoV-2 virus particles in saliva or exhaled breath. The approach uses an aptamer attached to a biosensor to selectively recognize and capture viruses, providing lower cost and reduced time to diagnose infections.
Researchers at Wayne State University have found that SARS-CoV-2 can induce fetal immune responses in pregnant women, even if they don't display symptoms. This increase in inflammatory markers poses a risk for preterm birth, stillbirth, and other complications.
A study shows that UK government trust, social norms, and privacy concerns play a significant role in the adoption of the NHS Covid-19 app. Initial enthusiasm to adopt the app was higher in urban locations, while people's concern about third-party data access fuelled reluctance to use it.
A research team has found a new dual benefit mode of action for the drug candidate Zapnometinib or ATR-002, which can inhibit SARS-CoV-2 virus proliferation and reduce exaggerated immune responses.
A Canadian study published in JAMA found a very low incidence of false-positive results among rapid antigen tests used to serially screen asymptomatic workers. The study showed only 0.05% of over 900,000 tests administered had false-positive results.
A new study sheds light on the molecular interactions between remdesivir and various viruses, revealing why it works against SARS-CoV-2 but not others like influenza. The findings aim to develop broad-spectrum therapies for future pandemics.
Researchers identified 40 peptide pairs with potential cross-reactivity between BCG vaccination and SARS-CoV-2, offering a new strategy to complement existing COVID-19 vaccines. These peptides can induce T cell responses and INF-γ production, providing long-lasting immunity against viral infections.
Researchers have detected the Delta variant of SARS-CoV-2 in the blood and placentas of women who experienced stillbirths and serious pregnancy complications. The study found that the virus was widely disseminated, causing severe inflammation of the placenta and leading to stillbirths.
Researchers at UCSF have identified a new potential drug target, BRD2, which regulates the ACE2 receptor, a key entry point for SARS-CoV-2. Blocking production of BRD2 prevents virus from infecting various human cell types.
The COVID-19 pandemic poses significant risks to pregnant women and their newborns, particularly due to viral-induced inflammation in the placenta. Studies have linked SARS-CoV-2 infection to adverse pregnancy outcomes, including stillbirth and severe neonatal illness, which may vary with specific circulating variants.
A study led by the Institute for Systems Biology found that unvaccinated pregnant people with COVID-19 are more likely to have poor birth outcomes, including preterm birth and stillbirth. The risk of these outcomes is particularly high for infections during the first or second trimester.
New research highlights key differences between COVID-19 variants alpha and omicron, including the impact on virulence and disease severity. The study suggests that omicron's genetic makeup is less conducive to causing severe illness compared to its older variant sibling, alpha.
A new study found that people experiencing increased stress, anxiety, and depression during the pandemic were more likely to contract Covid-19 and experience severe symptoms. The research, led by Professor Kavita Vedhara, suggests that psychological distress may be a significant factor in increasing susceptibility to viral respiratory ...
Researchers at the University of Central Florida found that face masks can reduce airborne pathogens' travel distance by more than half, suggesting they can effectively prevent airborne diseases. The study's findings could aid in managing responses to pandemics like COVID-19.
Researchers estimated severe SARS-CoV-2 outcomes in youths tested positive in emergency departments, highlighting key risk factors. The study found higher risks of severe illness among younger patients with underlying health conditions.
Researchers developed a passive air sampler clip to estimate airborne virus concentrations, detecting SARS-CoV-2 in five out of 62 volunteers. The device could serve as a semiquantitative screening tool for assessing personal exposure and identifying high-risk areas.
A unique Irish study found that previous COVID-19 infection and age are associated with lower antibody levels six months after vaccination. The research highlights the importance of boosting vaccinations for vulnerable populations like nursing home residents.
A study led by Georgetown University scientists demonstrates the power of artificial intelligence in predicting viruses that could infect humans, such as SARS-CoV-2. The research team identified 40 new bat hosts of betacoronaviruses and found that models harnessing data on bat ecology performed well at predicting new hosts.
Researchers found that T cells induced by previous common cold coronavirus infections can recognize and target internal proteins of SARS-CoV-2, providing a potential new vaccine target. This immunity offers long-lasting protection as T cell responses persist longer than antibody responses.
The Omicron variant is more transmissible than the Delta variant, spreading to individuals with two vaccine doses and previously infected individuals. A booster dose of Pfizer or AstraZeneca vaccine significantly increases antibody levels that can neutralize Omicron.
A University of Massachusetts Amherst study found that vaccinated women transfer SARS-CoV-2 antibodies to their breastfed infants, potentially giving them passive immunity against the coronavirus. The research also showed a correlation between vaccine side effects and antibody levels in infant stool.
A registry study found that people with inflammatory RMDs, such as rheumatoid arthritis and psoriatic arthritis, tolerate their COVID vaccine well, with short-lived reactions being the most common side effect. The majority of participants were able to continue on their normal medication with no changes.
The study investigated the antibody response to 2 or 3 doses of the BioNTech-Pfizer vaccine in patients with solid tumors treated with anticancer agents. The researchers found that higher antibody levels were associated with better immune response and reduced risk of severe COVID-19.
A booster dose of mRNA COVID-19 vaccine is required to provide immunity against the Omicron variant of SARS-CoV-2, according to a study. The traditional dosing regimens of COVID-19 vaccines available in the US do not produce antibodies capable of recognizing and neutralizing the Omicron variant.
Researchers developed a color-coded test that quickly signals whether medical nanoparticles deliver their cargo into target cells. The tool, tested in mouse cells and living mice, assesses nanoparticle formulations on their ability to escape cellular defenses and reach the cell's interior.
Birth during pandemic but no in utero exposure shows differences in neurodevelopment at 6 months. Maternal COVID-19 affects infant brain development
A study conducted at nine day care centers in Germany investigated the feasibility of SARS-CoV-2 surveillance testing among children and childcare workers. The test was found to be highly effective in identifying infected individuals and preventing further transmission.
Researchers have developed an at-home COVID-19 test with a high-quality assay that can detect the virus with similar reliability to laboratory-based molecular tests. The new test uses loop-mediated isothermal amplification and has unique advantages, such as speed and direct detection of viral RNA in saliva.
Experts from Charité – Universitätsmedizin Berlin will deliver SARS-CoV-2 tests and train laboratory staff to monitor the Mu variant, which has spread widely throughout Colombia. The team will also support local authorities with antibody testing and knowledge transfer to inform pandemic control decisions.
Researchers found that people infected with COVID-19 develop a wide variety of autoantibodies up to six months after recovery, and these autoantibodies persist over time. The study suggests that understanding these autoantibody responses could help identify ways to treat and prevent long-term symptoms.
A new study found that COVID-19 vaccination during pregnancy elicits high levels of antibodies in both mother and baby, regardless of when it occurs. The research suggests that pregnant women should not delay vaccination until late pregnancy, as it is likely to be beneficial for themselves and their babies.
A study published in JAMA Internal Medicine found that people with immune dysfunction, such as HIV infection or rheumatoid arthritis, had a higher rate of COVID-19 breakthrough infections after vaccination. These individuals also experienced worse outcomes compared to those without immune dysfunction.
A study at the University of Helsinki found that the APOE4 allele may increase cerebral microhaemorrhages and mental fatigue in COVID-19 patients. The risk of developing severe COVID-19 more than doubled in carriers of this allele.
Researchers identified antibodies targeting conserved sites on the spike protein, showing promise against future variants. Antibodies from vaccinated individuals retained some activity, while those with prior infection had reduced effectiveness.
Researchers found scarring in COVID-19 patients' kidneys, which may lead to long-term kidney outcomes. The virus directly causes cell damage, independent of the immune system, according to a new study published in Cell Stem Cell.
Researchers have discovered that individuals with a specific HLA type can mount a strong killer T cell response to COVID-19 due to cross-reactivity with seasonal coronaviruses. This finding may lead to the development of new vaccines targeting this immune response.
Researchers have found COVID-19 infection in white-tailed deer in six northeast Ohio locations, suggesting the virus may be spreading among wildlife. The study's findings indicate that infected deer can potentially harbor new strains of SARS-CoV-2, complicating human mitigation and control plans.
The SARS-CoV-2 Alpha variant adapted to avoid triggering the innate immune response by increasing expression of antagonism proteins, which disable the body's first line of defense. This allows the virus to replicate under the radar in early stages of infection, significantly increasing its chances of infecting a person.
A UTEP research team found SARS-CoV-2 neutralizing antibodies in over a third of Texas deer blood samples, indicating widespread infection among white-tailed deer. The study suggests that deer should not be neglected as a possible source of human infection.
A new study reveals that mRNA vaccines activate a type of helper cell called T follicular helper cells, which assist in creating powerful antibodies and drive the development of immune memory. This strong response helps prevent severe disease and death, even against highly mutated variants like omicron.
A new study finds that the Omicron variant can evade immunity from previous infections and vaccines, with antibodies from double-vaccinated individuals showing reduced neutralizing activity. The study suggests the need for new vaccines and treatments to combat evolving variants.
A new study found that infection-fighting B cells retain better memory of the coronavirus spike protein in patients who recover from less-severe cases of COVID-19 than those recovering from severe cases. This hints at subtle differences in the quality of immune response based on COVID-19 severity.
A study of 18 Connecticut colleges found that COVID-19 cases were associated with higher social contact and lower testing rates. The authors suggest that colleges should continue testing residential students and implementing mitigation strategies.
A recent study led by Harvard Medical School researchers found significant racial and ethnic disparities in hospital mortality for both COVID-19 and non-COVID patients. Hispanic Medicare patients were more likely to die from COVID-19, while existing pre-pandemic disparities widened during the crisis.
A new study reveals that SARS-CoV-2 limits viral particle release and instead spreads through cell-to-cell transmission, enabling efficient infection without the need for antibodies. This stealthy transmission method makes it challenging for the host immune system to target and neutralize the virus.
A phase 3 trial has shown that one dose of the Ad5-nCoV COVID-19 vaccine is highly effective against severe disease, with an efficacy rate of 91.7% at 28 days post-vaccination. The vaccine has also been found to be safe, with no serious vaccine-related adverse events or deaths reported among trial participants.